Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

NCT ID: NCT03891446

Last Updated: 2025-08-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

455 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-27

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR or who received commercial DURYSTA (Bimatoprost SR) in the open-label Phase 4 ARGOS study (MED-MA-EYE-0648) and completed (or exited early from) the study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Open-Angle Glaucoma Ocular Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lead-in study 192024-091 or -092 or -095

Study eye (Eye that received Bimatoprost SR in the lead-in study): No treatment is administered.

Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Fellow eye will receive only standard of care, based on the investigator's judgment.

Group Type EXPERIMENTAL

Standard of Care

Intervention Type OTHER

Standard of care treatment based on investigator's judgement.

Lead-in study 192024-093 Stage 1

Participants who received 1, 2 or 3 administrations and participants in Stage 2 who received 1 Bimatoprost SR administration due to safety concern or received 2 administrations.

Study eye (Eye that received Bimatoprost SR in the lead-in study): No treatment is administered.

Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Fellow eye will receive only standard of care, based on the investigator's judgment.

Group Type EXPERIMENTAL

Standard of Care

Intervention Type OTHER

Standard of care treatment based on investigator's judgement.

Lead-in study 192024-093 Stage 2

Participants who received 1 Bimatoprost administration due to sustained efficacy:

Study eye (Eye that received Bimatoprost SR in the lead-in study): 1 additional administration of Bimatoprost SR may be administered through completion of the Month 12 visit, at least 4 months apart from the lead-in study administration. Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Fellow eye will receive only standard of care, based on the investigator's judgment.

Group Type EXPERIMENTAL

Bimatoprost SR

Intervention Type DRUG

Intraocular implant

Standard of Care

Intervention Type OTHER

Standard of care treatment based on investigator's judgement.

Lead-in study ARGOS

Study eye (Eye that received Bimatoprost SR first in the lead-in study): 1 additional administration of Bimatoprost SR may be administered through completion of the Month 12 visit, at least 4 months apart from the lead-in study administration.

Treated Fellow eye (Eye that received Bimatoprost SR second in the lead-in study): 1 additional administration of Bimatoprost SR may be administered through completion of the Month 12 visit, at least 4 months apart from the lead-in study administration.

Untreated Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Untreated fellow eye will receive only standard of care, based on the investigator's judgment.

Group Type EXPERIMENTAL

Bimatoprost SR

Intervention Type DRUG

Intraocular implant

Standard of Care

Intervention Type OTHER

Standard of care treatment based on investigator's judgement.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bimatoprost SR

Intraocular implant

Intervention Type DRUG

Standard of Care

Standard of care treatment based on investigator's judgement.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

DURYSTA

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants who completed 1 of the 4 Bimatoprost SR Phase 3 studies (192024-091, -092, -093, or -095) and received Bimatoprost SR.
* Participants who completed (or exited early from) the open-label Phase 4 ARGOS study with no ongoing safety concerns, and received DURYSTA.

Exclusion Criteria

* Female participants who are pregnant, nursing, or planning a pregnancy, or who are of childbearing potential and not using a reliable means of contraception during the study.
* Concurrent or anticipated enrollment in another investigational drug or device study during the present study.
* Any condition which would preclude the participant's ability to comply with study requirements, including completion of the study.
* Participants who were randomized to receive timolol eye drops in the study eye (control group) during the Phase 3 Bimatoprost Studies 192024-091 and -092.
* For patients from the ARGOS lead-in study: history of prior incisional glaucoma surgeries and/or minimally invasive glaucoma surgical procedures in the study eye or treated fellow eye.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AbbVie

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ABBVIE INC.

Role: STUDY_DIRECTOR

AbbVie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Trinity Research Group /ID# 240190

Dothan, Alabama, United States

Site Status

Arizona Eye Center - West Ray Road /ID# 240239

Chandler, Arizona, United States

Site Status

Arizona Glaucoma Specialists /ID# 240212

Phoenix, Arizona, United States

Site Status

M&M Eye Institute /ID# 240236

Prescott, Arizona, United States

Site Status

Horizon Eye Specialists & Lasik Centers /ID# 240255

Sun City, Arizona, United States

Site Status

Angeles Eye Institute /ID# 250397

Culver City, California, United States

Site Status

Duplicate_Lakeside Vision Center /ID# 240204

Irvine, California, United States

Site Status

Hamilton Glaucoma Center Shiley Eye Center UCSD /ID# 240196

La Jolla, California, United States

Site Status

The Eye Research Foundation /ID# 240186

Newport Beach, California, United States

Site Status

North Bay Eye Associates Inc. /ID# 248912

Petaluma, California, United States

Site Status

Duplicate_Martel Eye Medical Group /ID# 240291

Rancho Cordova, California, United States

Site Status

The Clinical Trials Network (CTNx) /ID# 240284

Redding, California, United States

Site Status

Sacramento Eye Consultants /ID# 240263

Sacramento, California, United States

Site Status

Pacific Eye Associates /ID# 240234

San Francisco, California, United States

Site Status

Wolstan & Goldberg Eye Associates /ID# 240221

Torrance, California, United States

Site Status

Colorado Eye Institute /ID# 248910

Colorado Springs, Colorado, United States

Site Status

Specialty Retina Center /ID# 240254

Coral Springs, Florida, United States

Site Status

Nature Coast Clinical Research - Crystal River /ID# 240334

Crystal River, Florida, United States

Site Status

Bruce Segal, MD /ID# 240292

Delray Beach, Florida, United States

Site Status

Eye Associates of Fort Meyers /ID# 240218

Fort Myers, Florida, United States

Site Status

Levenson Eye Associates Inc. /ID# 240209

Jacksonville, Florida, United States

Site Status

MedEye Associates /ID# 240333

Miami, Florida, United States

Site Status

Logan Ophthalmic Research Inc. /ID# 240280

Tamarac, Florida, United States

Site Status

International Research Center /ID# 240346

Tampa, Florida, United States

Site Status

University of South Florida- Neuroscience Institute /ID# 250980

Tampa, Florida, United States

Site Status

Duplicate_Emory University /ID# 240328

Atlanta, Georgia, United States

Site Status

Coastal Research Associates /ID# 240192

Roswell, Georgia, United States

Site Status

Chicago Eye Specialists /ID# 240270

Bedford Park, Illinois, United States

Site Status

University of Illinois at Chicago /ID# 250981

Chicago, Illinois, United States

Site Status

Kovach Eye Institute /ID# 250442

Elmhurst, Illinois, United States

Site Status

IN Univ School of Medicine /ID# 240294

Indianapolis, Indiana, United States

Site Status

The Eye Care Institute /ID# 240289

Louisville, Kentucky, United States

Site Status

Duplicate_Tulane University /ID# 240327

New Orleans, Louisiana, United States

Site Status

Clinical Eye Research of Boston LLC /ID# 240203

Winchester, Massachusetts, United States

Site Status

Fraser Eye Center /ID# 240245

Fraser, Michigan, United States

Site Status

Midwest Vision Research Foundation at Pepose Vision Institute /ID# 250402

Chesterfield, Missouri, United States

Site Status

Tekwani Vision Center /ID# 240220

St Louis, Missouri, United States

Site Status

Eye Associates of North Jersey /ID# 250445

Dover, New Jersey, United States

Site Status

Glaucoma Care Center /ID# 250978

Livingston, New Jersey, United States

Site Status

Rutgers New Jersey Medical School Campus, Doctors Office Center /ID# 240181

Newark, New Jersey, United States

Site Status

Eye Associates of New Mexico /ID# 240216

Albuquerque, New Mexico, United States

Site Status

Ophthalmic Consultants Long Island /ID# 240211

Oceanside, New York, United States

Site Status

Rochester Ophthalmological Group PC /ID# 240290

Rochester, New York, United States

Site Status

Glaucoma associates/consultants of the capital region /ID# 240195

Slingerlands, New York, United States

Site Status

Montefiore Hospital /ID# 240324

The Bronx, New York, United States

Site Status

Asheville Eye Associates /ID# 240202

Asheville, North Carolina, United States

Site Status

Charlotte Eye,Ear,Nose Throat /ID# 240339

Belmont, North Carolina, United States

Site Status

Albemarle Clinical Trials LLC /ID# 240219

Elizabeth City, North Carolina, United States

Site Status

Private Practice - Dr. James D. Branch /ID# 240188

Winston-Salem, North Carolina, United States

Site Status

Bergstrom Eye Research LLC /ID# 240257

Fargo, North Dakota, United States

Site Status

Oklahoma Eye Surgeons /ID# 250430

Oklahoma City, Oklahoma, United States

Site Status

Legacy Devers Eye Institute /ID# 240210

Portland, Oregon, United States

Site Status

Scott and Christie and Associates /ID# 240189

Cranberry Township, Pennsylvania, United States

Site Status

Eye Specialty Group /ID# 240241

Memphis, Tennessee, United States

Site Status

Vanderbilt Eye Institute /ID# 252659

Nashville, Tennessee, United States

Site Status

Advancing Vision Research /ID# 240288

Smyrna, Tennessee, United States

Site Status

Keystone Research LTD /ID# 240185

Austin, Texas, United States

Site Status

Houston Eye Associates /ID# 240340

Houston, Texas, United States

Site Status

DCT Shah Eye Research Institut /ID# 240306

Mission, Texas, United States

Site Status

Plano Office /ID# 240243

Plano, Texas, United States

Site Status

San Antonio Eye Center /ID# 240238

San Antonio, Texas, United States

Site Status

Eye associates /ID# 240265

San Antonio, Texas, United States

Site Status

Medical Center Ophthalmology Associates /ID# 240208

San Antonio, Texas, United States

Site Status

Emerson Clinical Research Institute. LLC /ID# 240274

Falls Church, Virginia, United States

Site Status

Piedmont Eye Center /ID# 240187

Lynchburg, Virginia, United States

Site Status

Vistar Eye Center /ID# 240198

Roanoke, Virginia, United States

Site Status

Consultorio Oftalmologico Dr. Fabian Lerner /ID# 240247

CABA, Buenos Aires, Argentina

Site Status

Clinica Privada de Ojos /ID# 240272

Mar del Plata, Buenos Aires, Argentina

Site Status

Hospital Universitario Austral /ID# 240331

Pilar, Buenos Aires, Argentina

Site Status

Oftalmología Global /ID# 240244

Rosario, Santa Fe Province, Argentina

Site Status

Oftar Mendoza /ID# 240308

Mendoza, , Argentina

Site Status

Universitair Ziekenhuis Leuven /ID# 240312

Leuven, Vlaams-Brabant, Belgium

Site Status

Hospital de Olhos de Mato Grosso Do Sul /ID# 240276

Campo Grande, Mato Grosso do Sul, Brazil

Site Status

Clinica De Oftalmologia Nova Campinas /ID# 240271

Campinas, São Paulo, Brazil

Site Status

Hospital Oftalmologico Medicina dos Olhos /ID# 240277

Osasco, São Paulo, Brazil

Site Status

Hospital Sao Paulo /ID# 240278

São Paulo, , Brazil

Site Status

Queen Elizabeth II Health Sciences Centre - Victoria General /ID# 240336

Halifax, Nova Scotia, Canada

Site Status

Ophthalmic Consultant Centres /ID# 240205

Mississauga, Ontario, Canada

Site Status

Clinica de Oftalmologia Sandiego /ID# 240233

Medellín, Antioquia, Colombia

Site Status

Fundacion Oftalmologica Nacional /ID# 240226

Bogotá, Bogota D.C., Colombia

Site Status

Fundacion Oftalmologica de Santander - FOSCAL /ID# 240634

Bucaramanga, Santander Department, Colombia

Site Status

Ocni klinika Pardubice /ID# 240347

Pardubice, , Czechia

Site Status

Rigshospitalet Glostrup /ID# 240330

Glostrup Municipality, Capital Region, Denmark

Site Status

Bostan Diagnostic Eye Center /ID# 240268

Cairo, , Egypt

Site Status

Duplicate_Ain Shams University Hospital /ID# 240338

Cairo, , Egypt

Site Status

CHU Bordeaux - Hopital Pellegrin /ID# 240316

Bordeaux, Nouvelle-Aquitaine, France

Site Status

Centre Ophtalmologique Pôle Vision /ID# 240256

Écully, Rhone, France

Site Status

Internationale Innovative Ophthalmochirurgie /ID# 240232

Düsseldorf, North Rhine-Westphalia, Germany

Site Status

Universitaetsklinikum Magdeburg /ID# 240314

Magdeburg, , Germany

Site Status

The Chinese University of Hong Kong /ID# 240283

Hong Kong, , Hong Kong

Site Status

Galilee Medical Center /ID# 251967

Nahariya, Northern District, Israel

Site Status

Tel Aviv Sourasky Medical Center /ID# 240311

Tel Aviv, Tel Aviv, Israel

Site Status

Rambam Health Care Campus /ID# 240332

Haifa, , Israel

Site Status

Bnai Zion Medical Center /ID# 240297

Haifa, , Israel

Site Status

The Lady Davis Carmel Medical Center /ID# 240293

Haifa, , Israel

Site Status

AOU Policlinico G. Rodolico - San Marco /ID# 240305

Catania, , Italy

Site Status

ASL 2 Abruzzo Lanciano-Vasto-Chieti /ID# 240217

Chieti, , Italy

Site Status

Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia /ID# 240310

Perugia, , Italy

Site Status

Azienda Ospedaliero Universitaria Pisana /ID# 240301

Pisa, , Italy

Site Status

Capital Eye Specialists /ID# 240259

Wellington, , New Zealand

Site Status

Centro Oftalmologico Macula Diagnostico and Tratamiento /ID# 240269

Lima, , Peru

Site Status

Asian Eye Institute /ID# 240213

Makati City, , Philippines

Site Status

Asian Eye Institute /ID# 240214

Makati City, , Philippines

Site Status

Peregrine Eye and Laser Institute /ID# 240260

Makati City, , Philippines

Site Status

Oftalmika sp. z o.o. /ID# 240201

Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

Site Status

Klinika Diagnostyki i Mikrochirurgii Jaskry /ID# 240258

Lublin, Lublin Voivodeship, Poland

Site Status

Duplicate_Optimum Profesorskie Centrum Okulistyki Sp. z o.o. /ID# 240307

Gdansk, Pomeranian Voivodeship, Poland

Site Status

Centrum Diagnostyki i Mikrochirurgii Oka - LENS sp. z o.o /ID# 240248

Olsztyn, Warmian-Masurian Voivodeship, Poland

Site Status

S. Fyodorov Eye Microsurgery Federal State Institution /ID# 240251

Novosibirsk, Novosibirsk Oblast, Russia

Site Status

Clinical ophthalmology hospital n.a. V.P. Vihodtsev. /ID# 240253

Omsk, Omsk Oblast, Russia

Site Status

Singapore National Eye Centre /ID# 240224

Singapore, , Singapore

Site Status

Pretoria Eye Institute - Private Practice /ID# 240223

Pretoria, Gauteng, South Africa

Site Status

Asan Medical Center /ID# 240286

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Samsung Medical Center /ID# 240335

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Duplicate_Seoul National University Hospital /ID# 240262

Seoul, , South Korea

Site Status

Hospital Universitario Reina Sofia /ID# 240322

Córdoba, Cordoba, Spain

Site Status

Hospital Clinico San Carlos /ID# 240303

Madrid, , Spain

Site Status

Hospital Universitario Virgen Macarena /ID# 240325

Seville, , Spain

Site Status

Maharaj Nakorn Chiang Mai Hospital /ID# 240194

Chiang Mai, , Thailand

Site Status

Thammasat University Hospital /ID# 240231

Pathum Thani, , Thailand

Site Status

Eskisehir Osmangazi University Medical School /ID# 240225

Eskişehir, , Turkey (Türkiye)

Site Status

Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 240296

Istanbul, , Turkey (Türkiye)

Site Status

Addenbrookes Hospital /ID# 240351

Cambridge, Cambridgeshire, United Kingdom

Site Status

Duplicate_NHS Lothian /ID# 240318

Edinburgh, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Belgium Brazil Canada Colombia Czechia Denmark Egypt France Germany Hong Kong Israel Italy New Zealand Peru Philippines Poland Russia Singapore South Africa South Korea Spain Thailand Turkey (Türkiye) United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-003597-26

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

2023-504601-36-00

Identifier Type: OTHER

Identifier Source: secondary_id

1698-302-007

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.